INTRODUCTION
============

Atrial fibrillation (AF) carries a significant risk of stroke and heart failure and is associated with substantial morbidity and mortality ([@b14-0060332]; [@b48-0060332]). Up to 30% of patients with AF have a family history of the condition, suggesting that the disease has a broad genetic basis ([@b8-0060332]; [@b28-0060332]; [@b31-0060332]). Cases of 'lone' AF, defined by the presence of sustained arrhythmia in the absence of structural heart disease or other identifiable causes in patients younger than 65 years of age, further underscore the contribution of genetic variation to the development of AF ([@b36-0060332]). Recent studies have identified both common and rare genetic variants contributing to AF susceptibility. Positional cloning and candidate gene approaches have implicated mutations in genes encoding ion channels, gap junctions and signaling molecules in isolated cases and small kindreds ([@b1-0060332]; [@b17-0060332]; [@b22-0060332]). Genome-wide association studies (GWAS) have also recognized AF susceptibility loci ([@b12-0060332]) on chromosomes 4q25 near *PITX2* ([@b18-0060332]; [@b42-0060332]), 1q21 in *KCNN3* ([@b11-0060332]) and 16q22 in *ZFHX3* ([@b19-0060332]). Even so, most cases of lone AF remain of unknown etiology, are poorly penetrant, and segregate in isolated cases or small families, rendering the identification of causative genes and the design of new therapeutic strategies particularly challenging ([@b10-0060332]). Moreover, there is a paucity of functional modeling of known variants that could be used to draw putative molecular and cellular pathways contributing to AF symptoms.

In many cases of AF, electrical signals initiate in ectopic atrial locations, often close to the muscle sleeves of the pulmonary veins ([@b20-0060332]; [@b25-0060332]). Pulmonary veins and pulmonary myocardium develop from pharyngeal mesoderm, a process that depends on transcription factor *PITX2* ([@b27-0060332]; [@b32-0060332]). Recent evidence suggests that aberrant activation of embryonic mechanisms of atrial and pulmonary myocardium development can lead to AF ([@b33-0060332]) and genetic studies have linked *PITX2* to AF patients ([@b18-0060332]; [@b42-0060332]). Heterozygote *Pitx2* knockout mice, which have only 40% lower *Pitx2* expression than wild types, are also prone to arrhythmias, indicating that even modest changes in Pitx2 protein levels might promote AF ([@b23-0060332]).

During development, Pitx2 expression is regulated by BMP signaling ([@b16-0060332]; [@b34-0060332]; [@b45-0060332]). It was previously shown that the secreted BMP antagonist Grem2 ([@b37-0060332]; [@b49-0060332]) is highly expressed in pharyngeal mesoderm ([@b35-0060332]), similarly to *PITX2*, suggesting that GREM2 might modulate BMP signaling, thus acting upstream of PITX2. To test this possibility, and evaluate potential involvement of GREM2 in AF, we re-sequenced the GREM2 coding region in families of the Vanderbilt AF Registry ([@b9-0060332]). We discovered a GREM2 variant in two independent probands with familial AF with a higher frequency than found in the general population. To assess whether the variant contributes to AF, we investigated the role of GREM2 in cardiac development and assayed the arrhythmogenic potential of the GREM2 variant in animal models *in vivo* and cultured cells *in vitro*. Our results show that during embryonic development in zebrafish Grem2 is required for proper *pitx2* expression, cardiac laterality and atrial differentiation. GREM2 Q76E overactivity results in slower cardiac contraction rates and induction of previously identified AF candidate genes. These findings show that aberrant GREM2 activity probably contributes to AF, providing mechanistic insights into the pathogenesis of the disease.

###### TRANSLATIONAL IMPACT

**Clinical issue**

Atrial fibrillation (AF) is the most prominent heart arrhythmia and carries a significant risk of stroke and heart failure. It affects 2-5 million people in the United States, including young individuals (primarily in an idiopathic form) and older individuals (usually as a complication of various cardiovascular diseases). In most cases of AF, electrical signals begin in aberrant trigger areas, often close to the pulmonary veins. As the molecular causes of AF are not well understood, current treatments are mostly empiric. In addition, treatments can carry significant risks, are frequently ineffective or provide only temporary symptom relief.

**Results**

By sequencing the gene encoding the bone morphogenetic protein (BMP) antagonist Gremlin-2 (GREM2) in a cohort of idiopathic AF patients, the authors discovered a Q76E variant that increases the capacity of GREM2 to inhibit BMP signaling. The authors went on to analyze this human mutation in a zebrafish model, and assessed its function in live hearts. They made the novel finding that GREM2 is a crucial regulator of the cardiac rhythm gene network that acts upstream of Pitx2 (an important AF-promoting transcription factor). Additional in vivo experiments showed that GREM2 hyperactivity specifically slows conduction velocity in the atrium, without affecting ventricular contraction.

**Implications and future directions**

These results provide important novel mechanistic insights into the pathogenesis of AF. In addition, they provide a new platform for drug development. A major challenge in modern medicine is to understand how the patchwork of genetic variation in each human patient eventually leads to disease. This work provides an experimental template to evaluate the pathologic contribution of genetic variants in AF, and might contribute to finding new AF treatments.

RESULTS
=======

Presence of a GREM2 Q76E variant in two independent probands with lone AF
-------------------------------------------------------------------------

To identify new variants contributing to AF, we sequenced a cohort consisting of 193 probands with lone AF for *GREM*2 and identified a single c.226C\>G variant in two independent probands ([@b9-0060332]; [Table 1](#t1-0060332){ref-type="table"}). C.226C\>G is a rare variant (rs142343894) with a significantly higher frequency in the AF cohort than found in the general population represented by 1560 subjects in the 1000 Genomes Project (0.5% compared to 0.03%, *P*=0.034) ([@b7-0060332]; [@b30-0060332]) ([Fig. 1A](#f1-0060332){ref-type="fig"}; [supplementary material Table S1](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.010488/-/DC1)). C.226C\>G is a missense mutation within exon 2 of the *GREM2* gene that results in substitution of glutamine 76 for glutamic acid (Q76E). BMP antagonists such as GREM2 share the same overall protein structure as BMP ligands. Q76 is highly conserved across species and adjacent to C73, the first of the group of six cysteine residues that form the cystine knot motif required for protein folding, dimerization and interaction with BMP receptors ([@b3-0060332]) ([Fig. 1B,C](#f1-0060332){ref-type="fig"}).

###### 

Clinical characteristics of AF patients

![](DMM010488T1)

![**Identification of GREM2 variant in probands with lone AF.** (A) Pedigrees of two families with AF and probands heterozygous for the *GREM2* c.226C\>G variant allele that segregates in one of the families. Symbols indicate phenotypes as follows: solid, positive for AF; open, unaffected at \>65 years of age. Due to the variable expressivity of AF and late onset of symptoms, patients age \<65 years are considered to be of undetermined phenotype and are indicated by gray shading (A-III, B-III). Chromatographs are of proband carrying the Q76E mutation in GREM2 and wild-type control. (B) Protein model of GREM2 indicates the position of the amino acid substitution (red). The location of the six cysteines of the cystine knot are marked in green. Two additional cysteines C\' and C" linking adjacent loops are indicated, as well as the unpaired C~x~ in the heel of the cysteine knot. The Q76E substitution is immediately adjacent to the conserved first cysteine (C73) of the cystine-knot motif at the base of the first of the two loops. (C) Sequence alignment shows that the Q76E substitution is in a highly conserved glutamine (Q) residue across species. (D) Relative expression levels of *ID2* in HEK293 cells transfected with decreasing amounts of plasmids expressing wild-type GREM2 or GREM2-Q76E and treated with BMP4 recombinant protein. GREM2-Q76E decreased *ID2* expression at lower levels than wild-type GREM2, suggesting that the variant was more potent at antagonizing BMP than wild-type GREM2. \*\*\**P*\<0.0001 versus no BMP4; ^\#\#^*P*\<0.01, ^\#\#\#^*P*\<0.0001 versus wild-type GREM2.](DMM010488F1){#f1-0060332}

The Q76E variant increases the inhibitory activity of GREM2
-----------------------------------------------------------

To determine whether the p.Q76E variant alters the ability of GREM2 to antagonize BMP signaling, we transfected expression plasmids carrying wild-type *GREM2* or *GREM2-Q76E* into human embryonic kidney cells. We then exposed cells to recombinant BMP4 and assessed induction of *ID2*, a prototypical BMP signaling gene target. At maximum expression levels, both wild-type and variant GREM2 efficiently inhibited BMP signaling; however, by titrating the amount of transfected plasmids, we found that at lower concentrations the Q76E variant was at least twofold more potent at antagonizing BMP than wild-type GREM2 ([Fig. 1D](#f1-0060332){ref-type="fig"}). These data suggest that the Q76E substitution generates a hypermorphic allele.

Grem2 is required for asymmetric cardiac development and atrial differentiation in zebrafish
--------------------------------------------------------------------------------------------

Recent studies have implicated GREM2 in placode neurogenesis and craniofacial patterning ([@b24-0060332]; [@b52-0060332]). However, its role in cardiac development and cardiac function is unknown. To address this issue, we turned to the zebrafish model that offers excellent genetic and embryological tools for studying cardiac structure and function *in vivo*. By examining the expression of *grem2* and cardiac-specific genes, we found that *grem2* was present in the ventral portion of the pharyngeal arch mesoderm, immediately adjacent to the cardiac field, at the time that cardiac progenitor cells migrate from the midline to the left side of the embryo ([Fig. 2](#f2-0060332){ref-type="fig"}). Because BMPs are known to modulate proliferation and differentiation of cardiac progenitor cells ([@b6-0060332]; [@b46-0060332]), the juxtaposition of the Grem2-positive and cardiac territories raised the possibility that Grem2 shapes the gradient of BMP activity across the migratory path of developing cardiomyocytes and thus affects their fate.

![**Expression of*grem2*in pharyngeal arch primordia during cardiac tube migration.** (A,B) Whole mount images of *grem2* (purple)- and *cmlc2* (red)-stained embryos in dorsal (A) and lateral (B) views, anterior to the left. *grem2* is expressed in the first two pharyngeal arches (blue arrows point to the left first arch, black arrows to the left second arch) as the cardiac progenitors begin to assemble in the midline. During cardiac jogging to the left, the heart tube (yellow arrowhead) is positioned next to *grem2*-expressing pharyngeal mesoderm and subsequently passes ventrally to the *grem2*-expression domain in the left first pharyngeal arch. (C) Cross-sections of zebrafish embryos double-labeled for *grem2* and *cmlc2*. h, hours post fertilization; A, anterior; P, posterior; nt, neural tube; y, yolk.](DMM010488F2){#f2-0060332}

To test this possibility, we employed loss-of-function approaches in zebrafish using morpholino antisense oligonucleotides (described in [supplementary material Fig. S1](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.010488/-/DC1)). We found that depletion of *grem2* led to randomization of the cardiac axis, jogging and looping defects, as well as varied shape of the heart tube ([Fig. 3A](#f3-0060332){ref-type="fig"}). Replacement experiments with zebrafish or mouse mRNAs rescued the morpholino defects, suggesting that the phenotype was specific to loss of Grem2 function ([supplementary material Figs S2, S3](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.010488/-/DC1)). In zebrafish *grem2* morphants, expression of both *atrial*- and *ventricular-specific myosin heavy chains* (*amhc* and *vmhc*) was reduced, with *amhc* being more affected. The deficits in cardiac gene expression at 19 hours post-fertilization (hpf) was consistent with a smaller atrium in older embryos (48 hpf), as evaluated by antibody staining of ventricular and atrial tissues ([Fig. 3B](#f3-0060332){ref-type="fig"}). In addition, expression of *pitx2*, which controls cardiac laterality ([@b13-0060332]; [@b43-0060332]), was bilaterally upregulated when cardiac progenitors occupy the concentric territory adjacent to the midline, whereas the expression of the nodal antagonist *lefty2*, which is asymmetrically expressed on the left side when the cardiac tube has jogged to the left ([@b5-0060332]), was absent ([Fig. 3B](#f3-0060332){ref-type="fig"}). Grem2 does not appear to be required for asymmetric gene activity during early developmental stages, as illustrated by the normal left side expression of the nodal gene *spaw* in posterior mesoderm at 16 hpf ([supplementary material Fig. S4](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.010488/-/DC1)). These data indicate that Grem2 depletion results in abnormal expression of *pitx2* and *lefty2*, leading to cardiac laterality defects. In addition, atrial development appears to be particularly sensitive to Grem2 depletion.

![**Loss of Grem2 leads to cardiac jogging and looping defects, aberrant expression of*pitx2*and abnormal development of cardiac chambers.** (A) *In situ* hybridization analysis using *cmlc2* riboprobe shows that in wild-type (WT) embryos the heart jogs leftward, whereas cardiac morphogenesis is randomized in *grem2* morphants (*grem2* MO). The cardiac tube, consisting of a single atrium (A, white arrowheads) and a single ventricle (V), is thinner, shorter and fails to loop in *grem2* morphants. Left/Right (L/R) axis orientation is indicated. (B) *In situ* hybridization analysis using *vmhc* and *amhc* riboprobes shows that loss of Grem2 leads to lower expression levels of both *vmhc* and *amhc*, with *amhc* being essentially absent at 19 hpf (arrowheads). *Pitx2* expression (black arrowheads) at 19 hpf is enhanced (white arrowheads), whereas *lefty2* expression at 24 hpf is abolished (black arrowheads). Quantification of expression levels in wild-type and morphant embryos is shown below the corresponding images (expression is relative to wild type, which was set as arbitrary value 1). Immunofluorescence analysis using MF20 (red, labels both ventricular and atrial cardiomyocytes) and S46 (green, labels only atrial cardiomyocytes, which appear yellow) antibodies shows abnormal development of both chambers, with the atrium being more deformed and reduced in size than the ventricle. Arrowheads mark the position of the atrio-ventricular boundary. Scale bars: 50 μm. \**P*\<0.05.](DMM010488F3){#f3-0060332}

Grem2 regulates BMP signaling activity in cardiac development
-------------------------------------------------------------

Previous work has shown that precise levels of BMP signaling are necessary for cardiac morphogenesis ([@b6-0060332]). To test whether Grem2 regulates BMP signaling during zebrafish cardiac development, we analyzed phosphorylated Smad1/5/8 (pSmad) proteins, the main intracellular mediators of activated BMP signaling. We found strong pSmad protein upregulation in the somitic boundaries ([Fig. 4A](#f4-0060332){ref-type="fig"}) and the heart of *grem2* morphants compared with wild-type controls ([Fig. 4B](#f4-0060332){ref-type="fig"}), suggesting that Grem2 plays a key role in modulating BMP signaling during cardiogenesis. To test whether attenuation of the high BMP signaling levels in *grem2* morphants could reverse the cardiac deficits, we exposed *grem2*-depleted embryos to dorsomorphin (DM), a chemical inhibitor of BMP signaling ([@b21-0060332]) and analyzed cardiac development using *cmlc2* and *amhc* riboprobes. Incubation of *grem2* morphants with DM restored the expression domains of cardiac genes to levels comparable with wild-type embryos, particularly in the atrium ([Fig. 4C](#f4-0060332){ref-type="fig"}), whereas DM had no effect on wild-type, DMSO-treated control embryos at concentrations used in these experiments. Furthermore, the differentiation of the atrial bulb itself was restored in 65% of the DM-treated morphants, as assessed by the size of the heart area and the appearance of the morphological characteristics of the atrial bulb ([Fig. 4C,D](#f4-0060332){ref-type="fig"}). These data show that aberrantly high BMP signaling in *grem2* morphants is responsible, at least in part, for the observed cardiac defects and that Grem2 is a crucial regulator of BMP signaling during cardiac development and essential for atrial patterning and differentiation.

![**Loss of Grem2 leads to increased BMP signaling and cardiac defects that can be reversed by the BMP inhibitor dorsomorphin.** (A) Whole mount immunohistochemistry using antibodies recognizing the phosphorylated forms of Smads1/5/8 shows stronger pSmad protein staining in *grem2* morphants than in controls. Arrowhead marks somite boundaries. (B) Frontal close up views of the heart after pSmad1/5/8 antibody staining at 48 hpf shows sharply increased nuclear staining in cardiomyocytes of Grem2-depleted embryos. The heart is outlined by dotted lines; arrowheads mark pSmad-positive nuclei. (C) Wild-type (WT) embryos and *grem2* morphants were incubated with dorsomorphin or its vehicle DMSO between 16 and 48 hpf and stained at 48 hpf with *cmlc2* and *amhc* probes to visualize the ventricle (V) and atrium (A). Dorsomorphin treatment restored atrial patterning and differentiation (arrowheads point to the atrioventricular boundary in wild-type hearts; dotted lines demarcate ventricle-atrium boundary in *grem2* morphants). (D) Quantification of heart size (Heart Area) and atrial bulb restoration (Presence of Atrial Bulb) in DMSO-treated controls (WT), DMSO-treated *grem2* morphants (MO) and *grem2* morphants treated with dorsomorphin (MO+DM). Dorsomorphin treatment restores atrial development. Error bars represent s.d. *P*-values and number of embryos analyzed (*n*) are indicated. b, brain; e, eye; m, mouth; y, yolk.](DMM010488F4){#f4-0060332}

Grem2 overexpression expands atrial cardiomyogenesis
----------------------------------------------------

To establish whether Grem2 is sufficient to induce atrial formation in developing embryos, we overexpressed Grem2 by injecting *grem2* mRNA into one-cell-stage *cmlc2-egfp* transgenic zebrafish embryos and evaluated cardiac gene expression. Resultant embryos showed cardiac development not only in its native location, but also contractile activity in ectopic areas in the posterior trunk at 48 hpf ([Fig. 5A](#f5-0060332){ref-type="fig"}). At earlier stages (13 hpf), we observed supernumerary expression domains of *gata-5*, a transcription factor that promotes cardiac specification in mesodermal progenitor cells ([@b40-0060332]) ([Fig. 5B](#f5-0060332){ref-type="fig"}). These results indicate that Grem2 is sufficient to induce ectopic cardiomyogenesis in mesodermal progenitor cells. To determine the molecular characteristics of the ectopic cardiac territories, we stained *grem2*-overexpressing embryos with *amhc* and *vmhc* riboprobes ([Fig. 5C](#f5-0060332){ref-type="fig"}). The expanded ectopic myocardium expressed exclusively atrial *mhc* (*amhc*), whereas ventricular *mhc* (*vmhc*) expression in the native hearts was significantly reduced as compared with wild type, indicating that high Grem2 activity promotes atrial development and differentiation.

![**Overexpression of Grem2 induces ectopic atrial myocardium.** (A) Lateral view of live wild-type (WT) and *grem2* mRNA-injected (15 pg) *cmlc2-egfp* transgenic embryos (*grem2* OE) at 48 hpf shows ectopic cardiac tissue (arrowhead). Anterior-posterior (A/P) and dorsal-ventral (D/V) axes are indicated. (B) *In situ* hybridization shows ectopic sites expressing *gata-5* along the paraxial mesoderm (arrowheads). (C) WT zebrafish embryos were injected with *grem2* mRNA at the 1-4 cell stage; non-injected embryos served as controls. At 24 hpf, Grem2 overexpression (OE) led to enlarged or ectopic (arrowhead) *amhc* expression in 100% of injected embryos, whereas *vmhc* expression was reduced (arrow) or absent in 54.4%. These results remained consistent at 48 hpf, with 96% of embryos displaying ectopic *amhc* expression (arrowhead), and 52.2% displaying reduced *vmhc* expression (arrow). Insets display enlarged frontal images. Normal atrium (A) expressing *amhc* and ventricle (V) expressing *vmhc* are marked; dorsal (24 hpf) and lateral (48 hpf) views; anterior is to the left in all panels.](DMM010488F5){#f5-0060332}

GREM2 Q76E variant is arrhythmogenic
------------------------------------

The role of Grem2 in zebrafish atrial development, as well as the association between human GREM2-Q76E and AF, led us to hypothesize that, in addition to its role in cardiac morphogenesis, GREM2 is an upstream regulatory factor of the genetic network controlling cardiac rhythm. To test this possibility, we compared the expression levels of previously identified AF candidate genes ([@b2-0060332]; [@b15-0060332]; [@b17-0060332]; [@b18-0060332]; [@b22-0060332]; [@b47-0060332]) in differentiated mouse embryonic stem cells stably transfected with empty vector (control), human wild-type GREM2 and variant GREM2-Q76E expressing plasmids ([Fig. 6A](#f6-0060332){ref-type="fig"}). The results show that the expression levels of AF candidate genes were significantly increased by wild-type and variant GREM2, supporting the hypothesis that GREM2 regulates genes essential for maintaining cardiac rhythm.

![**GREM2 activity regulates cardiac rhythm.** (A) Stable mouse embryonic stem cell lines, generated with empty vector (control) or vectors expressing wild-type GREM2 or GREM2-Q76E, were allowed to form embryoid bodies. RNA was then isolated at differentiation day 8 and analyzed by qRT-PCR. The results showed that overexpression of GREM2 and GREM2-Q76E leads to upregulation of genes encoding calcium channel, voltage-dependent, L type, alpha 1C subunit (*Cacna1c*), natriuretic atrial peptide (*Nppa*), potassium voltage-gated channel subfamily E member 2 (*Kcne2*), connexin-40 (*Gja5*) and sarcolipin (*Sln*). (B) Quantification of cardiac contraction rates *in vivo* in *Tg*(*cmlc2:EGFP*) zebrafish embryos overexpressing human GREM2 and GREM2-Q76E variant. Both wild-type GREM2 and GREM2-Q76E slowed contraction rates, but the effect was more pronounced in GREM2-Q76E-injected embryos. (C) Digital cardiography of *Tg*(*cmlc2:EGFP*) zebrafish at 48 hpf showed regular ventricular rhythm and discordant atrial rhythm in wild-type *GREM2* and variant *GREM2-Q76E* injected embryos (arrows). (D) Tracking of two points in the proximal (1) and distal (2) atrium over time with quantification of time spent by each point in systole showed that the time spent in systole was not disrupted in the proximal point, but was significantly increased in the distal point in both wild-type (WT) and variant-injected embryos, suggesting a possible deterioration of the contraction wave as it traveled across the atrium. \**P*\<0.05, \*\**P*\<0.001, \*\*\**P*\<0.0001 versus control; \#*P*\<0.01, \#\#*P*\<0.001 versus wild-type GREM2.](DMM010488F6){#f6-0060332}

GREM2 levels are crucial for normal cardiac rhythm
--------------------------------------------------

To determine the functional impact of the GREM2 and GREM2-Q76E on cardiac rhythm, we assessed contraction rates in zebrafish embryos injected with human wild-type *GREM2* or *GREM2-Q76E* mRNAs. We found that contraction rates were significantly slower in embryos overexpressing either form of GREM2 compared with non-injected controls, but the effect was more pronounced in variant than wild-type *GREM2*-injected embryos ([Fig. 6B](#f6-0060332){ref-type="fig"}).

To evaluate whether the observed abnormal contraction rate defect reflects irregular rhythm, abnormal contraction signal propagation, or uncoupling of atrial from ventricular contractions, we developed a method of optical digital cardiography (DCG) for *in vivo* quantification of heart function in zebrafish. We found that the sequential rhythms of atrium and ventricle were synchronized and thus not perturbed by *GREM2* or *GREM2-Q76E* overexpression ([Fig. 6C](#f6-0060332){ref-type="fig"}; [supplementary material Movies 1-3](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.010488/-/DC1)). However, quantification of the DCG output showed that although ventricular rhythm remained regular, the atrial rhythm was consistently abnormal in *GREM2*- and *GREM2-Q76E*-injected embryos ([Fig. 6C](#f6-0060332){ref-type="fig"}; [supplementary material Movies 1-3](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.010488/-/DC1)). We concentrated our analysis on morphologically normal hearts; however, it is noteworthy that the severity of the arrhythmias increased in morphologically abnormal hearts (not shown). Overall, these data support the hypothesis that GREM2 regulates cardiac rhythm in the atrium, and establish that higher than normal GREM2 activity, either by overexpression or gain-of-function mutations such as the Q76E variant, have arrhythmogenic potential.

To probe the mechanism of irregular atrial contraction, we investigated whether contraction signal propagation was disrupted by assessing spatiotemporal conduction velocity on two distant test points, upstream (point 1) and downstream (point 2) along the contraction wave of the atrium ([Fig. 6D](#f6-0060332){ref-type="fig"}). We found that upstream contraction velocities were similar in all three conditions (control, wild type, variant), whereas downstream contraction velocities were slowed in hearts overexpressing GREM2 or variant GREM2-Q76E as compared with controls. Thus, it appears that high GREM2 activity distorts atrial contraction velocity and wavefront propagation.

DISCUSSION
==========

Advanced genetics approaches and sequencing tools have identified a broad spectrum of genetic variation in the coding region of human genes. The current challenge of modern medicine is to determine the contribution of individual pathogenic variants to complex diseases such as familial AF. Our analysis of the GREM2 variant Q76E and the cardiac imaging approaches developed here provide a template for functional modeling of AF-associated variants in zebrafish and differentiating embryonic stem cells. Moreover, because GWAS studies have linked the *GREM2* genetic locus to coronary vascular disease ([@b51-0060332]), the characterization of the role of GREM2 in cardiac development and function might have broader implications for understanding the contribution of BMP signaling and its specific modulators to cardiovascular health.

Specifically, our results show that Grem2, a BMP antagonist that is required for pharyngeal mesoderm patterning, is essential for zebrafish cardiac development. Loss of Grem2 leads to overexpression of *pitx2* and downregulation of *lefty2*, two crucial regulators of asymmetric cardiac development ([@b5-0060332]; [@b13-0060332]), randomizing jogging and looping. Moreover, Grem2 knockdown increases the levels of activated phosphorylated Smad and BMP signaling within cardiac cells, interfering with both ventricular and atrial differentiation. Atrial differentiation in particular is compromised at high levels of BMP signaling, but favored at low levels.

Our *in vitro* and *in vivo* data also support the notion that the GREM2 Q76E mutation generates a hypermorphic allele and a pathogenic genetic variant that increases the risk of AF. Although the allele shows poor penetrance, as often with AF loci, functional analyses in zebrafish revealed that higher than normal GREM2 levels expand atrial differentiation, but reduce cardiac contraction rates and disturb contraction propagation in atrial cardiomyocytes. Because the GREM2 Q76E variant appears to be a stronger BMP inhibitor than wild-type GREM2, it probably has no measurable effect at areas of high GREM2 expression, but might interfere with BMP signaling at border zones of GREM2 and BMP activity. In this setting, overactive GREM2 could promote ectopic differentiation of mesenchymal cells around pulmonary veins to sleeves of atrial muscle, and thus establish foci of ectopic arrhythmogenic activity. Alternatively, GREM2, by inhibiting BMP signaling, might function upstream to directly or indirectly downregulate *PITX2c* expression ([@b16-0060332]). Thus, increased GREM2 activity could lower *PITX2c* levels, altering the expression of atrial genes and raising the risk of AF.

Treatment of AF poses significant challenges, with a clear need for new therapeutic targets. The functional modeling of the human GREM2 mutation suggests that defective BMP signaling leads to AF, providing mechanistic insights into the pathogenesis of the disease and a host of novel therapeutic targets. To the best of our knowledge, GREM2 is the first morphogen implicated in cardiac laterality that also regulates cardiac contraction. This raises the intriguing possibility that the pathways establishing asymmetric cardiac development also control the genetic networks of cardiac rhythm, although the precise molecular mechanisms will need to be further investigated in future studies. These findings open new avenues for exploring the causes of AF, ultimately leading to better diagnostic and therapeutic strategies.

MATERIALS AND METHODS
=====================

Gene nomenclature
-----------------

Gene names in the text are according to nomenclature guidelines, with human genes in capitals (e.g. *GREM2*), mouse first letter capital (*Grem2*) and zebrafish in small letters (*grem2*). Gene names are in italic and protein names in roman font.

Study subjects and sample collection
------------------------------------

The study protocol was approved by the Vanderbilt University Institutional Review Board and participants took part after informed written consent was obtained. Patients ≥18 years of age with ECG-confirmed AF were enrolled in the Vanderbilt AF Registry, which comprises clinical and genetic databases ([@b9-0060332]). A detailed medical and drug history was obtained for all patients at enrollment. Clinical characteristics of study subjects are shown in [Table 1](#t1-0060332){ref-type="table"}.

Whole blood was collected for genomic DNA extraction and analysis. The *GREM2* coding and flanking regions were amplified by polymerase chain reaction (PCR) using primers 5\'-ACCAGATCAAGGAGGTGCTG-3\' and 5\'-AGAAGTGCTT-GCTGCTGAGG-3\', and analyzed using the Reveal Discovery System to identify aberrant conformers, which were then directly sequenced ([@b1-0060332]). Two unrelated lone AF subjects with *GREM2* variants were identified, namely a woman with persistent AF since age 62, and a man with AF since age 37. Both reported vagal triggers, with the former reporting post-prandial and nocturnal onset and the latter reporting nocturnal/ obstructive sleep apnea-related onset. As control cohort, subsections of BAM files from 1560 samples containing chromosome 1:240656549-240656551 were downloaded from 1000 Genome Project data (Exome alignment dated 2011-11-14) ([@b7-0060332]; [@b30-0060332]) and SNPs were called using SAMtools ([@b26-0060332]). The minor allele frequency (MAF) of the GREM2 Q76E (rs142343894) is 0.03% in the 1000 Genomes (1/3120) compared with 0.5% (2/193) in the Vanderbilt Registry of AF probands. Allele frequencies between 1000 Genome Project data and our re-sequencing data were compared using two-tailed Fisher\'s exact test.

Zebrafish maintenance
---------------------

Zebrafish, *Danio rerio*, were maintained as described ([@b35-0060332]). Zebrafish embryos were obtained from crosses between AB and TL lines or the *Tg(cmlc2:EGFP)twu34* line.

*In situ* hybridization and antibody staining
---------------------------------------------

Whole-mount *in situ* hybridization was performed as described ([@b35-0060332]; [@b50-0060332]). The hybridization mix for the double staining with *grem2* and *cmlc2* contained two digoxigenin-labeled RNA antisense probes for *grem2* (250 ng of *grem2* coding region probe and 500 ng *of grem2* 3\'-UTR probe per 250 μl of hybridization mix) and 250 ng of fluorescein-labeled *cmlc2* probe. For all other markers, we used 250 ng of digoxigenin-labeled RNA antisense probe per 250 μl hybridization mix.

Whole-mount antibody staining was performed as described ([@b29-0060332]; [@b44-0060332]). Mouse monoclonal antibodies MF20 against sarcomeric myosin heavy chain and S46 against atrial myosin heavy chain were obtained from the Developmental Studies Hybridoma Bank, diluted 1:10 in blocking solution, and applied to embryos overnight at 4°C. After five washes in PBS-Triton, embryos were incubated overnight at 4°C with secondary antibodies conjugated to AlexaFluor 488 and AlexaFluor 555 from Molecular Probes, diluted 1:400 in blocking solution. After six washes in PBT-DMSO, samples were transferred to 1:1 glycerol-PBT and stored at 4°C. Samples were incubated overnight at 4°C with anti-pSmad1/5/8 antibody (diluted 1:400 in blocking buffer; Cell Signaling Technology) then washed and incubated with pre-adsorbed alkaline phosphatase-conjugated goat anti-rabbit IgG (diluted 1:1000 in blocking buffer; Jackson ImmunoResearch) for 2 hours at room temperature.

To quantify changes in gene expression levels, signal intensity at the region of interest was measured in the green channel using NIH ImageJ. The background was subtracted and the signal normalized to non-injected, wild-type controls. Statistics were performed using the two-tailed Student\'s *t*-test, with *P*\<0.05 being considered significant.

Loss- and gain-of-function experiments and dorsomorphin treatment
-----------------------------------------------------------------

We used the following morpholino (MO) antisense oligonucleotides (Gene Tools) to block the splicing (MO1) and translation (MO2) of the zebrafish *grem2* transcript: MO1 5\'-ACTGCTCATC-CTGGAACACAGAGAG-3\' and MO2 5\'-ACACAGCGCCAC-CTTACTGCTCATC-3\' ([supplementary material Fig. S1](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.010488/-/DC1)). Morpholinos were reconstituted in water. Embryos at 1- to 4-cell stage were injected with 1 nl of morpholino solution into the yolk, close to the blastomeres, with an air injector from WPI (PV820 Pneumatic PicoPump). A concentration of 0.6 mM for MO1 or 0.4 mM for MO2 produced a fully penetrant and expressive phenotype in more than 85% of the injected embryos (morphants) without unspecific toxic effects.

Morphant embryos and non-injected controls were incubated in 2 μM dorsomorphin (Sigma-Aldrich) ([@b21-0060332]) dissolved in DMSO, or in DMSO alone, from 16 hpf until fixation at 48 hpf.

We injected 1 nl zebrafish *grem2* mRNA at 10-15 pg/nl into the yolk. Human wild-type and variant *GREM2* mRNAs were injected at various concentrations ranging from 2 to 5 pg/nl. *Grem2* overexpression caused the expected defect of lack of BMP signaling during early embryogenesis, i.e. dorsalization of embryos. Only embryos with mild dorsalized phenotypes were processed for molecular characterization at later stages in order to visualize cardiac defects. For all shown experiments, 2.5 pg/nl of human *GREM2* mRNA was used because we found it to be the highest concentration that resulted in normal cardiac morphology but abnormal rhythm.

Cardiac morphology and contractility in live embryos
----------------------------------------------------

For optical digital cardiography (DCG), live zebrafish *Tg*(*cmlc2:EGFP*)*twu34* embryos at 48 hpf were embedded into 1.5% agarose and continuous images of the whole heart were taken on a Axio Imager Z1 microscope with a EC Plan-Neofluar 5×/0.15 M27 lens for 30 seconds using Axiovision software (Zeiss). Files were then imported into ImageJ and converted to binary using the 'threshold' command. The atrium or ventricle was selected and the two-dimensional surface area was calculated for each frame using the 'analyze particles' command. The output values were collected and plotted in Microsoft Excel. Analysis was performed on four embryo hearts for each condition. To determine whether signal propagation was uniform across the atrium, we selected two points on the atrium: one near the location where the contraction wave begins (point 1), and one far from both the initiation site and the valve that the signal moves towards (point 2). Point 2 was at a 45° angle to the line drawn through the valve.

In order to track points 1 and 2, the two points were marked with a single pixel and the move of the pixel was measured in ∼100 successive frames using ImageJ to report the coordinates of each selected point. The coordinates were then plotted in Microsoft Excel, assigning as 0 the coordinate at the most expanded location (i.e. furthest distance from the valve) during diastole. The coordinates were then converted to distance values from location 0 and the distances plotted over time as a line chart. Thus, peak values in the middle chart of [Fig. 6D](#f6-0060332){ref-type="fig"} represent point locations at the end of systole.

In Grem2 overexpressing hearts, peaks corresponding to distal point 2 appeared broader than the peaks of proximal point 1, indicating that point 2 spent a longer time in systole than point 1 in overexpressing embryos. To quantify the average time that points 1 and 2 spent in systole, we calculated the size of peak areas above the mid-contraction point ([Fig. 6D](#f6-0060332){ref-type="fig"}, right panel).

Cloning of human wild-type and variant GREM2
--------------------------------------------

The *GREM2* wild-type coding sequence was amplified from human genomic DNA using forward primer 5\'-CTAGC[GAATTC]{.ul}A-TGTTCTGGAAGCTTTCCCTGTCCTTGTTC-3\' and reverse primer 5\'-CTAGC[GGATCC]{.ul}TCACTGCTTGTCCGAGTCGCT -CAGGTTCAC-3\'. Cloning sites *Eco*RI and *Bam*HI are underlined. The resulting amplicon was digested with *Eco*RI and *Bam*HI and cloned into pcDNA3.1/Myc-His(-)A (Invitrogen). The Q76E mutation was introduced with primers 5\'-AGTGACTG-GTGCAAGACGGAGCCGCTGCGGCAGACGG-3\' and 5\'-CCGTCTGCCGCAGCGGCTCCGTCTTGCACCAGTCACT-3\'. Successful cloning of wild-type GREM2 and GREM2-Q76E was confirmed by restriction enzyme digests and direct sequencing.

Cell culture
------------

Human embryonic kidney 293 (HEK293) cells were transiently transfected with 1, 25, 50 and 100 ng of wild-type GREM2 or GREM2-Q76E plasmids using Lipofectamine 2000 reagent (Invitrogen) and treated with 5 ng/ml BMP4 for 6 hours. RNA was then extracted and analyzed for *ID2* expression using quantitative RT-PCR. Lipofectamine 2000 (Invitrogen) was used to stably transfect undifferentiated CGR8 mouse embryonic stem cells with 8 μg of linearized wild-type GREM2 and GREM2-Q76E plasmids. Positive clones were selected with 200 μg/ml G418 for 10 days and single colonies were picked, expanded, and genotyped. CGR8 cells were cultured and differentiated using the hanging-drop method ([@b39-0060332]).

RNA preparation and qRT-PCR analysis
------------------------------------

Total RNA was extracted from mouse embryonic stem cells at day 8 of differentiation using the RNeasy kit (Qiagen) and reverse-transcribed into cDNA ([@b4-0060332]). For quantitative PCR, 20 ng of cDNA was amplified with the iQ SYBR Green Supermix kit on an iCycler (BioRad) using *β-actin* or *GAPDH* as controls. In addition, we normalized qPCR values in [Fig. 6](#f6-0060332){ref-type="fig"} to the relative expression levels of variant and wild-type *GREM2*. Relative gene expression levels were quantified using the formula 2^(-ΔΔCt)^ as described ([@b4-0060332]). Primer sequences are included in [supplementary material Table S2](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.010488/-/DC1).

Protein modeling
----------------

GREM2 structure was previously modeled on human sclerostin ([@b41-0060332]). We used the UCSF Chimera system for visualization of the GREM2 structure ([@b38-0060332]).

Statistical analysis
--------------------

Statistical analyses on continuous data were performed using unpaired two-tailed Student\'s *t*-test; analysis on categorical data were performed using two-tailed Fisher\'s exact test. qPCR results are shown as mean ± s.e.m. of data from at least three separate experiments, each performed with triplicate samples. Differences between groups were analyzed for statistical significance using one-way ANOVA with Bonferroni post-hoc test (GraphPad Prism software). *P*-values \<0.05 were accepted as statistically significant.
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